CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 25.13×, higher than 95% of its Biotechnology peers (median 5.71×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
784.79MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.2030xvs all stocks
52-Week Change
427.40%vs all stocks
Market Capitalization
784.79MUSDvs all stocks (USD)
Enterprise Value
553.68MUSDvs all stocks (USD)
Forward P/E
-12.81xvs Biotechnology peers
Price to Book (MRQ)
3.43xvs Biotechnology peers
Enterprise to EBITDA
-13.35xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-20.52%vs Biotechnology peers
Return on Equity (TTM)
-34.18%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-41.48MUSDvs all stocks (USD)
Net Income (TTM)
-39.92MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-38.50MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.39MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-29.96MUSDvs all stocks (USD)
Pre-tax Income
-29.40MUSDFY2025 · Dec 31, 2025Income Tax Expense
37.72KUSDFY2025 · Dec 31, 2025Net Income
-29.44MUSDFY2025 · Dec 31, 2025EBIT
-29.96MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.59MUSDFY2025 · Dec 31, 2025Research & Development
16.26MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
13.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
555.53KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-29.44MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-23.64MUSDFY2025 · Dec 31, 2025Free Cash Flow
-24.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
93.93MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-29.44MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
364.50KUSDFY2025 · Dec 31, 2025Stock-based Compensation
2.44MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.06MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.03MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-98.01KUSDFY2025 · Dec 31, 2025Capital Expenditures
-732.92KUSDFY2025 · Dec 31, 2025Purchase of Investments
-6.48MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-7.21MUSDFY2025 · Dec 31, 2025Other Financing Charges
-137.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
107.26MUSDFY2025 · Dec 31, 2025Shares Outstanding
71.19MSharesUpdated Sep 27, 2026Float Shares
56.17MSharesUpdated Sep 27, 2026Shares Short
9.62MSharesUpdated Sep 27, 2026Short Ratio
6.56daysvs all stocks
Short % of Shares Outstanding
16.24%vs all stocks
% Held by Insiders
17.13%vs all stocks
% Held by Institutions
79.01%vs all stocks
Total Cash (MRQ)
232.11MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.24USDUpdated Sep 27, 2026Total Debt (MRQ)
1.00MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0044xvs Biotechnology peers
Current Ratio (MRQ)
25.13xvs Biotechnology peers
Book Value per Share (MRQ)
3.20USDUpdated Sep 27, 2026Total Assets
104.84MUSDvs all stocks (USD)
Total Current Assets
101.24MUSDFY2025 · Dec 31, 2025Total Liabilities
11.04MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
933.63KUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.93MUSDFY2025 · Dec 31, 2025Other Short-term Investments
6.48MUSDFY2025 · Dec 31, 2025Accounts Payable
5.44MUSDFY2025 · Dec 31, 2025Short-term Debt
139.34KUSDFY2025 · Dec 31, 2025Long-term Debt
933.63KUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.30KUSDFY2025 · Dec 31, 2025Retained Earnings
-104.46MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
93.80MUSDvs all stocks (USD)
Treasury Stock
99.96KUSDFY2025 · Dec 31, 202552-Week Low
2.00USDUpdated Sep 27, 202652-Week High
15.10USDUpdated Sep 27, 202652-Week Change
427.40%vs all stocks
Beta
0.2030xvs all stocks
50-Day MA
11.47USDUpdated Sep 27, 2026200-Day MA
9.03USDUpdated Sep 27, 2026Avg 10-Day Volume
1.57MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.52MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.8800USDUpdated Sep 27, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 25.13×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 25.13Industry median: 5.71Industry P95: 22.21Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Youkeshu Technology Co. Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Surrozen, Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Heilongjiang Publishing & Media Co. Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets